| ²é¿´: 879 | »Ø¸´: 0 | |||
huangyan.88.гæ (СÓÐÃûÆø)
|
[½»Á÷]
ÄÚÖÊÍøÓ¦¼¤£¨ÎÒÃÇÉíÌåÄÚµÄËïÎò¿Õ£©
|
|
ÎÒÃÇÉíÌåµÄϸ°ûÎÞʱÎ޿̲»ÔںϳɴóÁ¿µ°°×ÖÊÓÃÓÚÖ´ÐÐÉúÎïѧ¹¦ÄÜ£¬¶øÕâÒ»¸ßÇ¿¶ÈµÄÉú²ú¹ý³Ì±ØÈ»»á²úÉúÒ»¶¨ÊýÁ¿µÄ¡°²Ð´ÎÆ·¡±£¬¼´Î´ÕÛµþµ°°×¼°´íÎóÕÛµþµ°°×¡£µ±´óÁ¿Î´ÕÛµþµ°°×¼°´íÎóÕÛµþµ°°×»ýÀÛʱ£¬Ï¸°û»áÈçºÎÓ¦¶ÔÕâ¸öÂ鷳Ĩ£¿ÕâʱÐèÒªÂ¡ÖØÍÆ³ö±¾ÆÚÖ÷½Ç¡ª¡ªÄÚÖÊÍøÓ¦¼¤£¨Endoplasmic reticulum stress£¬ERS£©¡£ ´ó¼ÒÁ˽âERSÂð£¿ERSÊÇÈçºÎ´¦ÀíδÕÛµþµ°°×¼°´íÎóÕÛµþµ°°×µÄÄØ£¿¼²²¡Ñо¿ÖУ¬ERSÈçºÎÓ°Ïì¼²²¡µÄ·¢Éú·¢Õ¹ÄØ£¿ERS¾ßÌåÔõô¼ì²âÄØ£¿²»ÖªµÀµÄ¿ì¸úÎÒÒ»ÆðÀ´Ñ§Ï°Ò»Ï塃 ERS£ºÒ»ÖÖ³ÖÐøµÄÄÚÖÊÍøÑ¹Á¦×´Ì¬£¡ µ±ÄÚÖÊÍøÖе°°×ÖʵÄÕÛµþ³öÏÖÎÊÌâʱ£¬Î´ÕÛµþ»ò´íÎóÕÛµþµÄµ°°×ÖÊÔÚÄÚÖÊÍøÖзÇÕý³£¾Û¼¯£¬¾Í»áÒý·¢ERS¡£¼òµ¥À´Ëµ£¬ERS¾ÍÊÇÒ»ÖÖϸ°û¶ÔÓÚÄÚÍâ»·¾³Ñ¹Á¦²úÉúµÄÓ¦¼¤·´Ó¦£¬¾ßÌåÊÇÔõô»ØÊ£¿ UPR¡¢ERADºÍAutophagy£ºÏ¸°ûͨ¹ý²»Í¬Í¾¾¶½ø»¯³öµÄµ°°×ÖÊÖÊÁ¿¿ØÖÆÏµÍ³ µ±Ï¸°ûÖдíÎóÕÛµþµ°°×ÖʵÄÊýÁ¿»ýÀÛ³¬¹ýÁÙ½çãÐֵʱ£¬ÎªÁ˻ָ´µ°°×ÖÊÎÈ̬»òµ°°×ÖÊÆ½ºâ£¬Ï¸°ûÓÖ»áͨ¹ý¶àÖÖÊÊÓ¦»úÖÆÊÔͼ¾ÀÕýÕâÖÖÇé¿ö£¬°üÀ¨£ºÎ´ÕÛµþµ°°×ÖÊ·´Ó¦£¨Unfolded Protein Response£¬UPR£©¡¢ÄÚÖÊÍøÏà¹Øµ°°×½µ½â;¾¶£¨ER-associated degradation£¬ERAD£©ºÍ×ÔÊÉ£¨Autophagy£©£¬ÆäÖÐ×îµäÐ͵ľÍÊÇUPR¡£ UPR£ºÔÚERSϾö¶¨Ï¸°ûÃüÔ˵ÄÐźÅͨ· µ°°×·´Ó¦µÄ¡°Èý´ó»¤ÎÀ¶Ó¡±»úÖÆÐÅÏ¢»ã×Ü ERSÑо¿ÏÖ×´ ÔÚÁ˽âÁËERS¼°ÆäÏà¹ØÐźŻúÖÆºó£¬Ïë±ØÄãÒ²ÅжϳöÁËERSÑо¿µÄÖØÒª³Ì¶ÈÁË¡£Ã»´í£¬ÎÒÃǶԽü20Äê·¢±íµÄÎÄÕ¼ìË÷·¢ÏÖ£¬¡°ÄÚÖÊÍøÓ¦¼¤¡±ÈȶȳÊ45¡ã½ÇÉÏÉýÖУ¬ÊôʵÊÇÒ»¿ÅȽȽÉýÆðµÄ¡°ÐÂÐÇ¡±¡£ ÔÚÁ˽âERS·¢ÎÄÊýÁ¿ºÍÑо¿Ç÷ÊÆºó£¬ÎÒÔÚΪ´ó¼Ò½²ÊöʲôÀàÐ͵ļ²²¡¿ÉÒÔ¹Ò¹³ERSÑо¿¡£ ´óÁ¿Ñо¿Ö¤¾Ý±íÃ÷£¬ERS½éµ¼µÄ·´Ó¦Í¾¾¶ÓëÐí¶àÈËÀ༲²¡µÄ·¢²¡»úÖÆÃÜÇÐÏà¹Ø£¬³ýÈ¥Ö×ÁöÀà¿ÉÒÔ¹ØÁªERSÍ⣬»¹ÓÐÉñ¾ÍËÐÐÐÔ¼²²¡¡¢¸Î²¡¡¢ÂýÐÔ´úл¼²²¡µÈ ½ÓÏÂÀ´´ø´ó¼ÒÁ˽âERSÔÚ¼²²¡»úÖÆÑо¿ÖеľßÌåÑо¿Ë¼Â·¡£ ÎÄÕÂÒ»£ºÌÇÄò²¡Éö²¡£¨DKD£©ÓëERS µÚһƪÎÄÕÂÓÚ2022Äê8Ô·¢±íÔÚ¡¶KIDNEY INTERNATIONAL¡·£¨IF=18.998£©ÉÏ£¬ÌâΪ¡°Reticulon-1A mediates diabetic kidney disease progression through endoplasmic reticulum-mitochondrial contacts in tubular epithelial cells¡±¡£ ¸ÃÑо¿½ÒʾÁËÄÚÖÊÍø×¤Áôµ°°×Reticulon-1A£¨RTN1A£©ÔÚÈËDKDÖеĹؼü×÷Ó㬼´´Ù½øRTN1A±í´ï¿Éͨ¹ýERS·´Ó¦´Ù½øÉöС¹ÜÉÏÆ¤Ï¸°û£¨TEC£©ËðÉË£¬¼ÓÖØDKD¡£Æä¾ßÌå»úÖÆÉæ¼°RTN1A¿Éµ÷½ÚER-ÏßÁ£Ìå¼äµÄ´®ÈÅ£¬¼´ÄÚÖÊÍøRTN1A¾ºÕùÐÔµÄÓëÏßÁ£ÌåÏà¹Øµ°°×HK1»¥×÷£¬¸ÉÈÅHK1-VDAC1»¥Ïà×÷Óã¬ÕâʹÍÑÀëÏÂÀ´µÄVDAC1¼¤»îÑ×ÐÔСÌåͨ·ºÍ´Ù½øÏ¸°ûµòÍö£¬¼ÓÖØDKD¼²²¡½øÕ¹¡£ RTN1A´Ù½øDKDÉöС¹ÜËðÉËÑо¿Ë¼Â· ÎÄÕ¶þ£º¹ÇÖÊÊèËÉÖ¢ÓëERS µÚ¶þƪÎÄÕ·¢±íÓÚ2022Äê11Ôµġ¶PHARMACOLOGICAL RESEARCH¡·£¨IF=10.334£©ÆÚ¿¯ÉÏ£¬ÌâΪ¡°Blocking the cytohesin-2/ARF1 axis by SecinH3 ameliorates osteoclast-induced bone loss via attenuating JNK-mediated IRE1 endoribonuclease activity¡±¡£ ¸ÃÑо¿½ÒʾÁË×è¶ÏCytohesin-2/ARF1ÖáÒÖÖÆÆÆ¹Çϸ°ûUPR·´Ó¦µÄ·Ö×Ó»úÖÆ¡£¾ßÌåΪCytohesin-2ͨ¹ýÓ°ÏìJNKͨ·µ÷¿ØIRE1µÄºËËáÄÚÇÐø»îÐÔ£¬´Ù½øIRE1/XBP1;¾¶£¬Ó°ÏìÆÆ¹Çϸ°û·Ö»¯¡£Òò´Ë¿Éͨ¹ýCytohesin-2ÒÖÖÆ¼ÁSecinH3×è°cytohesin-2/ARF1/JNK/p-IRE1;¾¶£¬´Ó¶øÒÖÖÆÆÆ¹Çϸ°û·Ö»¯£¬ÎªÖÎÁƹÇÖÊÊèËÉÌṩеIJßÂÔ¡£ Ñо¿Ë¼Â· Cytohesin-2µ÷½ÚÆÆ¹Çϸ°û·Ö»¯µÄÑо¿Ë¼Â· ERSÓÕµ¼¼Á¼°¼ì²â·½·¨ ÎÒÃÇ´ÓÎÄÏ×Öпɿ´³ö£¬ERS¿ÉÔÚʵÑéÌõ¼þϱ»Ò»Ð©»¯Ñ§ÎïÖÊÓÕµ¼·¢Éú£¬³£¼ûµÄERSÓÕµ¼¼ÁÓУºÒÂÃ¹ËØ£¨tunicamycin£¬TM£©¡¢¶¾ºúÂܲ·ËØ£¨thapsigargin£¬TG£©¡¢²¼À׷ǵ¾úËØA£¨Brefeldin A£¬BFA£©¡£ ÄÇôÈçºÎ¼ì²âERS£¿ÒÔÏÂΪÁ½ÖÖ³£Óõļì²â·½·¨£º Ò»ÖÖÊÇ»ùÓÚRNAµÄ·½·¨£¬·ÖÎöXBP1¼ôÇм°ÆäËûUPR»ùÒòµÄ±í´ï£» ÁíÒ»ÖÖÊǼì²âÏà¹Øµ°°×£¬¿ÉÒÔÁ˽âUPRµÄÄÄЩÐźÅ;¾¶±»ÒÖÖÆ»ò¼¤»î¡£ |
» ²ÂÄãϲ»¶
н®´óѧµØÖÊÓë¿óÒµ¹¤³ÌѧԺÕÐÉú
ÒѾÓÐ10È˻ظ´
Õе÷¼Á
ÒѾÓÐ11È˻ظ´
0856²ÄÁÏÓ뻯¹¤Çóµ÷¼Á£¡
ÒѾÓÐ11È˻ظ´
²ÄÁÏÓ뻯¹¤304Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
»¶Ó211±¾¿ÆÍ¬Ñ§£¬¹ýAÇø¹ú¼ÒÏߣ¬AÇø·ÇƫԶһ±¾£¬½»²æÑ§¿Æ¿ÎÌâ×é
ÒѾÓÐ23È˻ظ´
AÇøÒ»±¾½»²æ¿ÎÌâ×飬µÍ·Öµ÷¼Á£¬ÕÐÊÕ»úеµç×ÓÐÅϢͨÐŵȽ»²æ·½Ïò
ÒѾÓÐ31È˻ظ´
Öпƴó²ÄÁÏ299Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
301Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏ¿¼ÑÐ339Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏר˶290Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´













»Ø¸´´ËÂ¥
100